D155B4CA-927F-4B4F-B6BC-2D41267F195E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6.3731931668856765
- age_years
- 20
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.345
- HEDGEHOG_SIGNALING+0.324
- PROTEIN_SECRETION+0.319
- CHOLESTEROL_HOMEOSTASIS+0.251
- MTORC1_SIGNALING+0.183
- UV_RESPONSE_DN+0.183
- FATTY_ACID_METABOLISM+0.165
- ADIPOGENESIS+0.155
- SPERMATOGENESIS+0.146
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.136
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.454
- INTERFERON_GAMMA_RESPONSE-0.449
- ANGIOGENESIS-0.428
- TNFA_SIGNALING_VIA_NFKB-0.408
- INTERFERON_ALPHA_RESPONSE-0.383
- ALLOGRAFT_REJECTION-0.381
- COAGULATION-0.306
- INFLAMMATORY_RESPONSE-0.272
- E2F_TARGETS-0.268
- IL2_STAT5_SIGNALING-0.255
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | FD166A94-332D-426D-9E36-E4272F3772FC | — | — | 0.911 |
| 2 | 02F669D8-FB9F-45AF-A999-5886E5C2DAF0 | — | — | 0.906 |
| 3 | SRR934831 | — | — | 0.894 |
| 4 | 864D2BA3-EB33-4DC2-A228-4CADDCF526D4 | — | — | 0.882 |
| 5 | 79573301-2820-444D-9131-F47F081279C3 | — | — | 0.873 |
| 6 | 0876D5B1-AA68-4E43-8BBE-9EE2CDC6879E | — | — | 0.871 |
| 7 | 1D3FBEA0-9A7F-436C-AA71-366D4E11C43B | — | — | 0.861 |
| 8 | SRR1326179 | GTEX | — | 0.859 |
| 9 | 2CBB6A30-1BF8-4F58-A2C1-99AFA8685277 | — | — | 0.858 |
| 10 | SRR1340508 | GTEX | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.345 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.324 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.319 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.251 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.183 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.183 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.165 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.155 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.146 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.136 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.127 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.109 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.107 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.082 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.072 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.065 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.051 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.045 | Inavolisib | — uncovered |